Power3 Medical Products, Inc. (OTC:PWRM)
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). PWRM applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, PWRM has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Alzheimer's is one, among the common sort of dementia, an over-all term regarding loss of memory and various other intellectual abilities serious enough to interfere with routine daily life. Alzheimer's condition is the reason for 50 to 70 percent of dementia cases.
Alzheimer's disease just isn't an everyday aspect of increasing age, although the most significant identified risk factor is increasing age, and the most of individuals with Alzheimer's are 65 and older. Alzheimer's is not just an illness connected with senior years. As much as 5 percent of people with the actual condition have early-onset Alzheimer's (also called younger-onset), which frequently appears in an individuals 40's or 50's.
Worldwide, breast cancer comprises 10.4% of all cancer incidence among women, making it the most common type of non-skin cancer in women and the fifth most common cause of cancer death. In 2004, breast cancer caused 519,000 deaths worldwide (7% of cancer deaths; almost 1% of all deaths). Breast cancer is about 100 times more common in women than in men, although males tend to have poorer outcomes due to delays in diagnosis.
Parkinson’s disease typically effects people around fifty. The early signs of Parkinson’s tends to be subtle and also occur gradually. The condition moves along more rapidly in many people than in others. When the condition accelerates, the shaking, or tremors, which will has an effect on nearly all Parkinson’s individuals, may restrict every day actions.
Power3 Medical Products, Inc. management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer's and Parkinson's, to name a few.
Power3 Medical Products, Inc. plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into PWRM, with PWRM remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.
Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Rozetta-Cell has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.
To learn more about PWRM visit: http://www.Power3Medical.com
DARA BioSciences, Inc. (Nasdaq:DARA) has priced a public offering of up to 4800 units at a price of $1000 per unit to the public with each unit consisting of (1) one share of Series A convertible preferred stock which is convertible into 400 shares of our common stock (2) a Class A Warrant to purchase 200 shares of common stock and (3) a Class B Warrant to purchase 200 shares of common stock. Subject to certain ownership limitations, the Series A preferred stock is convertible at any time at the option of the holder into shares of our common stock at a conversion price of $2.50 per share. The Company has increased the size of the offering from the previously announced $4 million to up to $4.8 million.
Ladenburg Thalmann & Co., Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (AMEX:LTS), acted as the exclusive placement agent for this offering.
Class A Warrants are exercisable immediately after the date of issuance and expire five years after the date of issuance. Class A Warrants will entitle the holder to purchase shares of common stock for an exercise price equal to $2.50.
Class B Warrants are exercisable immediately after the date of issuance and expire one year after the date of issuance. Class B Warrants will entitle the holder to purchase shares of common stock for an exercise price equal to $2.50.
DARA BioSciences, Inc. is a Raleigh, North Carolina based biopharmaceutical development company that acquires promising therapeutic candidates and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND (Investigational New Drug) Applications from the United States FDA.
Crown Equity Holdings Inc. (OTCPK:CRWE)
Crown Equity Holdings Inc. announced recently that its subsidiary company, Crown Tele Services Inc. (http://www.crownteleservices.com) is still moving forward after dissolving its joint venture with Communication Expert Corporation and will gradually start rolling out its internet based voice and video service IP-PBX solutions next year.
The cornerstone of Crown Tele Services Inc. strategy is to meet the highest standards when it comes to delivering VoIP (Voice over Internet Protocol) communication solutions specifically designed to meet the market needs.
Commenting on the venture, Kenneth Bosket, president said, "We are still excited with this opportunity to expand our footprint in this valuable market. The demand for internet-based voice and video services is growing exponentially and our new subsidiary Crown Tele Services Inc. has launched its new website and intends to emerge as a service provider of choice."
According to ABI Research, the latest global business VoIP services forecasts show that the value of the overall market, which includes VoIP integrated access, SIP trunking, hosted IP-PBX/IP Centrex and managed IP-PBX services, is set to double over the next five years, to exceed $20 billion by 2015.
To learn more about CRWE visit: http://www.crownequityholdings.com
Grubb & Ellis Company (NYSE:GBE) announced that it has acquired Humble Surgical Hospital, a Class A, single-story, 30,000-square-foot surgical hospital in the Houston suburb of Humble. Located at 1475 FM 1960 East Bypass, Humble Surgical Hospital is a multi-specialty, physician owned medical center that relocated to its newly-renovated facility in August 2010. The hospital has the capacity to treat more than 1,000 cases per month and can provide comprehensive medical care. The facility includes six state-of-the-art operating rooms and two procedure rooms in which a variety of surgical services are performed, including: orthopedics, ophthalmology, podiatry, plastic surgery, pain management, chiropractics, spine and gastroenterology.
Grubb & Ellis Company, a commercial real estate services and investment management company, together with its subsidiaries, provides integrated real estate solutions, including transactions, management, consulting, and investment advisory services.
Carriage Services Inc. (NYSE:CSV) announced that it has acquired White's Funeral Home in Azusa, Los Angeles County, California from Ronald ("Ron") T. White. The business was established in 1917 by the White family and under the leadership of Ron, its third generation owner, continued its long standing reputation of exemplary service to the community. Ron and his wife, Sherril, will continue to be very active in the funeral home as consultants for Carriage Services.
Carriage Services, Inc. provides death care services and merchandise in the United States. It operates through two segments, Funeral Home Operations and Cemetery Operations.**********
Boston Scientific Corporation (NYSE:BSX) announced to scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco. Ray Elliott, President and Chief Executive Officer, will make a 25-minute presentation on Tuesday, January 11, 2011, beginning at approximately 9:30 a.m. PT. Following the presentation, Jeff Capello, Executive Vice President and Chief Financial Officer, will join Mr. Elliott in a question and answer session.
Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).